海普瑞(09989.HK):EXARANE取得泰國批准
格隆匯4月2日丨海普瑞(09989.HK)發佈公吿,旗下全資附屬公司深圳市天道醫藥有限公司生產的Exarane(集團依諾肝素鈉注射液領先藥物之一)已獲得泰國食品藥品監督管理局批准上市銷售。
公吿表示,本次獲批,代表集團海普瑞的依諾肝素鈉製劑將會於泰國市場進行銷售,將進一步提升集團依諾肝素鈉製劑在全球的市場佔有率。集團認為本次核准是集團製劑業務實施國際化佈局的另一個重要成果,再次證明集團進軍海外市場的能力。未來,集團將會持續發力,加速集團拓展全球市場的進程及銷售通路建設,為後續進一步加強海外市場發展做好鋪墊。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.